Traditionally, effective adaptive immune response against cancer requires the rendezvous between the tumor antigen/major histocompatibility complex expressed on mature dendritic cells (DC) traveling from the primary tumor site and the resident CD4+ and CD8+ T cells in the secondary lymphoid organs. The gene discussed is CD8A; the disease is neoplasm.